Pfizer (NYSE:PFE) recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Here is why it could be a smart buy now. Not every stock needs to be a millionaire-maker. Sometimes, slow and steady can win ...

Pfizer Inc. (NYSE:PFE – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the company, Marketbeat reports.

According to TipRanks, Meacham is a 3-star analyst with an average return of 0.5% and a 48.33% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, ...

Pfizer discontinues development of weight-loss pill. Investors now expect it to acquire VKTX to expand in the anti-obesity ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...